H pylori Infection

Latest Articles

Associations Between Gastrointestinal Infection and New-Onset IBD

By

Dibash Kumar Das, PhD

Certain enteric pathogens are associated with higher risk of incident inflammatory bowel disease, while others are could be protective.

RHB-105 Effective for Eradication of Helicobacter pylori in Adults

A novel rifabutin-based triple therapy (RHB-105) is effective for eradication of Helicobacter pylori, with eradication rates unaffected by resistance to clarithromycin or metronidazole.

High H. pylori Eradication Rate with Rifabutin-Based Therapy

By

Jessica Nye, PhD

A novel rifabutin-based therapy (RHB-105) may be a potential first-line defense against Helicobacter pylori (H. pylori) infection.

Gastric Intestinal Metaplasia: 2020 AGA Guidelines

By

Andy Kistler, MD, PharmD

The American Gastroenterological Association recently published new clinical practice guidelines on the management of gastric intestinal metaplasia.

10-Day Nonbismuth Effectively Treats H pylori

By

Jessica Nye, PhD

This study follows up to examine the implementation of a 14-day quadruple nonbismuth concomitant regimen to treat Helicobacter pylori, as proposed by recent Guidelines and Consensus Statements.

H pylori Prevalence and Associated Ulcers Continue to Decline

By

Lauren Dembeck, PhD

The prevalence of H pylori infection continues to fall in the general population with only 16% of all gastric and 25% of all duodenal patients with ulcer harboring H pylori.

Dual Therapy With Vonoprazan, Amoxicillin Effective For Helicobacter pylori

By

Jessica Nye, PhD

Dual therapy with vonoprazan and low-dose amoxicillin had similar efficacy to triple-drug treatment for the eradication of Helicobacter pylori.

Following Helicobacter pylori Infection, Gastric Cancer Risk High

By

Gastroenterology Advisor Contributing Writer

Individuals who are racial or ethnic minorities and individuals who are smokers experience significantly higher risks for gastric cancer following a diagnosis of Helicobacter pylori infection.

Helicobacter pylori Infection Must Be Wiped Out to Cut Gastric Cancer Risk

Only complete eradication of Helicobacter pylori infection, not treatment alone, will reduce the risk for developing stomach cancer.

Talicia Gets FDA Approval for Helicobacter Pylori Treatment

By

Diana Ernst, RPh

The FDA has approved Talicia (omeprazole magnesium, amoxicillin and rifabutin delayed-release capsules; RedHill Biopharma) for the treatment of Helicobacter pylori (H. pylori) infection in adults.

Disaggregation and Variability of Gastric Cancer Risk and Survival in Asian American Subgroups

By

Dibash Kumar Das, PhD

The researchers discovered significant differences and substantial heterogeneity in risk for GC among API subgroups. Substantial differences in all-cause survival among API subgroups were also observed.

Helicobacter Pylori Testing Should Include Patients With GERD From Endemic Areas

By

Gastroenterology Advisor Contributing Writer

The study researchers concluded that recommendations for Helicobacter pylori screening should also include patients who exhibit GERD symptoms only, irrespective of regional origin.

Review: H Pylori Treatment in Patients With Allergies, Coexisting Conditions

By

Diana Ernst, RPh

A recent review published in the journal Pharmacotherapy summarizes recommendations for the treatment of Helicobacter pylori infection in special patient populations.

H. Pylori Treatment May Reduce Gastric Cancer Incidence, Death

Reductions in gastric cancer mortality seen with H. pylori treatment, vitamin, garlic supplementation.

Gastric Microbiota Restoration Related to Eradication of Helicobacter pylori

By

Gastroenterology Advisor Contributing Writer

The impact of eradicated Helicobacter pylori on the pediatric gastric microbial community structure shows restoration of bacterial diversity consistent with noninfected children in the same endemic region.

T2DM Increases Gastric Cancer Risk After H. Pylori Eradication

Type 2 diabetes was linked to an increased risk for gastric cancer (adjusted hazard ratio, 1.73). Stratified statistical analysis demonstrated a significantly higher risk for gastric cardia cancer (adjusted hazard ratio, 3.40) and a significantly increased risk in those with suboptimal glycemic control (adjusted hazard ratio, 1.68).